Dennis J. Slamon

Oncology

10945 Le Conte Ave Ste 3360
Los Angeles, CA 90095

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 156 publications

Editor's Note: Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab In vitro and In vivo.

Editor's Note: Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab In vitro and In vivo.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: July 13, 2026

Mirvetuximab Soravtansine Exposure and Incidence of Cataract Surgery.

Mirvetuximab Soravtansine Exposure and Incidence of Cataract Surgery.

Journal: JAMA network open

Published: May 21, 2026

Inhibition of Acetyl-CoA-carboxylase induces endoplasmic reticulum stress and augments the efficacy of anti-cancer therapies.

Inhibition of Acetyl-CoA-carboxylase induces endoplasmic reticulum stress and augments the efficacy of anti-cancer therapies.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 16, 2026

Expression of HER2 in the eye and the potential for on-target side effects with antibody-drug conjugates.

Expression of HER2 in the eye and the potential for on-target side effects with antibody-drug conjugates.

Journal: Scientific reports

Published: December 19, 2025

Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial.

Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial.

Journal: JAMA oncology

Published: September 25, 2025

Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival.

Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival.

Journal: ESMO open

Published: September 18, 2025

Why Adjuvant Treatment With a CDK4/6 Inhibitor Should Be Recommended for Women With High-Risk Breast Cancer: Methodologic Considerations on Available Evidence.

Why Adjuvant Treatment With a CDK4/6 Inhibitor Should Be Recommended for Women With High-Risk Breast Cancer: Methodologic Considerations on Available Evidence.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 17, 2025

Tumor Cells Enriched for Interferon and Inflammatory Programs Pre-Exist in High Grade Serous Ovarian Cancer and are Proportionately Significantly Increased Post Chemotherapy.

Tumor Cells Enriched for Interferon and Inflammatory Programs Pre-Exist in High Grade Serous Ovarian Cancer and are Proportionately Significantly Increased Post Chemotherapy.

Journal: bioRxiv : the preprint server for biology

Published: July 16, 2025

A Decade After Approval of the First CDK4/6 Inhibitor: A Look Back at Palbociclib's Journey from Discovery to Approval and What's Next in CDK Inhibition in Breast Cancer.

A Decade After Approval of the First CDK4/6 Inhibitor: A Look Back at Palbociclib's Journey from Discovery to Approval and What's Next in CDK Inhibition in Breast Cancer.

Journal: Targeted oncology

Published: May 14, 2025

Intermediate endpoints as surrogates for long-term outcomes in breast cancer adjuvant chemotherapy trials.

Intermediate endpoints as surrogates for long-term outcomes in breast cancer adjuvant chemotherapy trials.

Journal: The oncologist

Published: May 07, 2025

Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients.

Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients.

Journal: Journal of the National Cancer Institute

Published: March 18, 2025

Pembrolizumab and epigenetic modification with azacitidine reshapes the tumor microenvironment of platinum-resistant epithelial ovarian cancer: a phase 2 non-randomized clinical trial.

Pembrolizumab and epigenetic modification with azacitidine reshapes the tumor microenvironment of platinum-resistant epithelial ovarian cancer: a phase 2 non-randomized clinical trial.

Journal: Communications medicine

Published: December 28, 2024

Showing 1-12 of 156

Last Updated: 09/26/2026